Stock markets torn between optimism over vaccines and discouragement over macro data

<p>
<a href="https://admiralmarkets.com/analytics/traders-blog/astrazeneca-advances-vaccine"><img data-resize="auto" data-resize="auto" data-resize="auto" style="width:auto;" data-src="https://fxmedia.s3.amazonaws.com/articles/Stock_markets_torn_between_optimism.jpg" alt="Stock markets torn between optimism over vaccines and discouragement over macro data" rel=""></a>
</p><p>
The main European indices' post mid-session gains are driven by the good news that continues to arrive around the vaccines against Covid-19. In the United States, <a href="https://admiralmarkets.com/start-trading/contract-specifications/instrument/_pfe" target="_blank">Pfizer</a> asked for authorization on Friday to commercialize its vaccine and the regulator could make it effective by mid-December, as it was made known this weekend.
</p><p>
For its part, AstraZeneca announced today that its vaccine, developed together with the University of Oxford, shows 90% efficacy in one of its trials by administering "half a dose, followed by a full dose with an interval of at least one month ".
</p><p>
Despite this announcement, the pharmaceutical company registered drops of 1.27% in the pre-opening of the market after closing last Friday with a rise of 2.35%.
</p><p>
<em><em data-redactor-tag="em"><img data-resize="auto" src="https://fxmedia.s3.amazonaws.com/articles/AstraZeneca_CFD_Weekly_Chart.png" rel="" alt="AstraZeneca CFD Weekly Chart" /></em></em>
</p><p>
<em><em data-redactor-tag="em">Source: Admiral Markets </em><a href="https://admiralmarkets.com/trading-platforms/metatrader-5" target="_blank"><em>MetaTrader 5</em></a><em>. AstraZeneca CFD Weekly Chart. Data range: from July 26, 2015, to November 23, 2020. Prepared on November 23, 2020, at 11 am. Keep in mind that past returns do not guarantee future returns.</em></em>
</p><p>
Indexes performed as follows:
</p><ul>
<li>The Italian FTSE MIB index is the one that registered the most gains in the middle of the session, with 1.2%</li>
<li>The German DAX rose 1.1%</li>
<li>Spanish IBEX 25 increased 1%</li>
<li>The French CAC 40 rose 0.9%</li>
<li>The FTSE 100 saw 0.4% gains</li>
</ul><p>
However, uncertainty and fear of the economic effects of the pandemic due to lockdowns continue to be very present in the minds of investors.
</p><p>
Today, IHS Markit's leading PMI index fell to 45.1 from 50.0 in October, the exact level that separates growth from contraction. "The economy of the euro zone has suffered a severe fall again in November amid renewed efforts to quell the growing wave of COVID-19 infections," Reuters reported. "The data increases the probability that the GDP of the euro area will contract again in the fourth quarter", they warn.
</p><p>
Do you think AstraZeneca will maintain the long-term uptrend or do you think there will be profit taking from investors? With Admiral Markets UK Ltd, you can speculate on the movement of AstraZeneca share prices both up and down through <a href="https://admiralmarkets.com/education/articles/cfd/cfd-trader" target="_blank">Contracts for Difference (CFDs)</a>. If you want to start you have two options: open a <a href="https://admiralmarkets.com/start-trading/forex-demo" target="_blank">free demo account</a> with virtual money or open a real trading account by clicking on the following banner:
</p><a href="https://admiralmarkets.com/start-trading"><img data-resize="auto" src="https://fxmedia.s3.amazonaws.com/articles/Live_Account-14.png" alt="Trade Forex &amp; CFDs" rel="" /><p><br></p></a><p><strong>INFORMATION ON ANALYTICAL MATERIALS:</strong></p><p><em>The data provided provides additional information on all analyzes, estimates, forecasts, forecasts, market reviews, weekly outlooks or other evaluations or similar information (hereinafter "Analysis") published on the Admiral Markets website. Before making any investment decisions, pay close attention to the following:</em></p><p><em>1. This is a marketing communication. The content is posted for informational purposes only and should not be construed as investment advice or recommendation. It has not been prepared in accordance with legal requirements designed to promote the independence of investment research, and is not subject to any prohibition on pre-dissemination of investment research.</em></p><p><em>2. Each investment decision is made by each client alone, while Admiral Markets UK Ltd (Admiral Markets) will not be liable for any loss or damage arising from such a decision, whether based on content or not.</em></p><p><em>3. In order to protect the interests of our clients and the objectivity of the Analysis, Admiral Markets has established relevant internal procedures for the prevention and management of conflicts of interest.</em></p><p><em>4. The analysis is prepared by an independent analyst, Carolina Caro, SEO implementer (hereinafter "Author") based on personal estimates.</em></p><p><em>5. While all reasonable efforts are made to ensure that all sources of content are reliable and that all information is presented, as much as possible, in an understandable, timely, accurate, and complete manner, Admiral Markets does not guarantee accuracy. or integrity of any information contained in the Analysis.</em></p><p><em>6. Any past performance or modelling of the financial instruments indicated in the content should not be construed as an express or implied promise, guarantee, or implication of Admiral Markets for any future performance. The value of the financial instrument may rise and fall, and the preservation of the asset's value is not guaranteed.</em></p><p><em>7. Leveraged products (including contracts for difference) are speculative in nature and may generate profit or loss. Before you start trading, make sure you fully understand the </em><a href="https://admiralmarkets.com/risk-disclosure" target="_blank"><em>risks</em></a><em>.</em></p>